HomeCLINICAL TRIALS, STUDIES, REGISTRIES, DATA

CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Balt Begin the STEM Trial: Receives IDE Approval From the FDA

The clinical trial is a prospective, randomized controlled trial.

Publication of TOBA III Clinical Trial Results in the Journal of Vascular Surgery

TOBA III Clinical Trial: “We are thrilled to have the TOBA III data published in the Journal of Vascular Surgery,” commented Peter Schneider, M.D., Co-Founder and Chief Medical Officer of Intact Vascular. “This peer-reviewed article adds to the strong body of evidence supporting use of the Tack Endovascular System for focal dissection repair when treating lesions both above- and below-the-knee.”

New Data Unveiled at Heart Rhythm 2020 Demonstrate Effectiveness of App-Based Remote Monitoring of Medtronic Cardiac Devices, Significant Reduction in Complications with Micra Leadless...

During the current COVID-19 pandemic, procedures, and therapies that reduce exposure to other people are important because that also reduces the potential for spreading the virus. The results were presented at the annual Heart Rhythm Society Scientific Sessions, held virtually for the first time.

PINNACLE FLX Study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device Presented as Late-Breaking Clinical Trial at HRS 2020 SCIENCE

PINNACLE FLX clinical trial assesses the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for patients with non-valvular atrial fibrillation

SERF VT Study Presented as Part of HRS 2020 Science Late-Breaking Clinical Trial Sessions

The SERF VT Study is underway in the U.S. at Mayo Clinic, Loyola University Medical Center, and Vanderbilt University Medical Center, and in Canada at Southlake Regional Health Centre, Montreal Heart Institute and Quebec Heart and Lung Institute.

Key Recruitment Milestones in ProActive Study and Success in Prospera Early Access Program Reports Natera

ProActive Study will follow 3,000 kidney transplant patients over a three to five year period to examine the utility of the Prospera donor-derived cell-free DNA (dd-cfDNA) transplant assessment test to accurately identify organ rejection.

iSTAR Medical MIGS Device Studies: Highly Promising in Glaucoma Patients

The two-year final outcomes from STAR-I trial and six-month results from its European trial STAR-II have been accepted for presentation at the European Glaucoma Society meeting, now postponed to December 2020 following the Covid-19 pandemic.

Thrive Earlier Detection Announces Groundbreaking Clinical Data from the First Ever Interventional Study of a Blood-Based Test to Screen and Identify Multiple Types of...

The study was conducted by Johns Hopkins University and Geisinger and enrolled more than 10,000 women with no prior history of cancer notes Thrive Earlier Detection.

Medtronic Onyx ONE Clear Study of One-Month Dual-Antiplatelet Therapy in High Bleeding Risk Stent Patients Beats Performance Goal

Medtronic Onyx ONE Clear Study met its primary endpoint of cardiac death or myocardial infarction by beating a performance goal derived from contemporary one-month DAPT trials at one-year post-procedure.